Institut de cancérologie Strasbourg Europe

Quick facts

Phase 3 pipeline

• Administration of L-TC · Oncology
  L-TC is a therapeutic cancer vaccine designed to stimulate the immune system to recognize and attack cancer cells.
• Paclitaxel + Trastuzumab · Oncology
  Paclitaxel works by inhibiting microtubule dynamics, thereby inducing cell cycle arrest and apoptosis in rapidly dividing cancer cells. Trastuzumab targets the HER2/neu receptor, which is overexpressed in certain breast cancer cells, and triggers antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity.
• Thero2-01S22
  Thero2-01S22's mechanism is unknown.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Institut de cancérologie Strasbourg Europe portfolio CI brief
• Institut de cancérologie Strasbourg Europe pipeline updates RSS